Koji Muramatsu
Overview
Explore the profile of Koji Muramatsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
627
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muramatsu K, Maruyama K, Honda Y, Katagiri H, Takahashi Y, Takahashi N, et al.
Med Mol Morphol
. 2025 Feb;
PMID: 39966172
Progastrin-releasing peptide (ProGRP), a neuropeptide, is a stable tumor marker for small cell lung carcinoma (SCLC) and other neuroendocrine tumors, such as medullary thyroid carcinoma. It has recently been reported...
2.
Hatakeyama K, Muramatsu K, Nagashima T, Ichida H, Kawanishi Y, Fukumura R, et al.
Sci Rep
. 2024 Jun;
14(1):13699.
PMID: 38871991
The detection of copy number variations (CNVs) and somatic mutations in cancer is important for the selection of specific drugs for patients with cancer. In cancers with sporadic tumor cells,...
3.
Deguchi S, Akiyama Y, Mitsuya K, Ikeya T, Hozumi C, Iizuka A, et al.
Anticancer Res
. 2024 Apr;
44(5):1983-1994.
PMID: 38677762
Background/aim: Brain metastasis, a leading cause of cancer death, is a clinical challenge. Recently, genetic characterization of brain metastatic lesions based on next generation sequencing-based advanced technologies, such as single-cell...
4.
Wakuda K, Morita M, Sekikawa M, Morikawa N, Miura K, Doshita K, et al.
Int J Clin Oncol
. 2024 Jan;
29(2):96-102.
PMID: 38183554
Background: Although various companion diagnostic tests of ALK fusion gene-rearrangement are approved, few reports have assessed the concordance of ALK fusion gene-rearrangement in two companion diagnostic tests: next-generation sequencing (NGS)...
5.
Hozumi C, Iizuka A, Ikeya T, Miyata H, Maeda C, Ashizawa T, et al.
Cancer Genomics Proteomics
. 2023 Dec;
21(1):88-101.
PMID: 38151294
Background/aim: Recently, inactivating somatic mutations of SWI/SNF chromatin-remodeling genes in cancers have been reported. However, few studies have been performed regarding the immunological analysis of the tumor microenvironment (TME) in...
6.
Terada Y, Isaka M, Ono A, Kawata T, Serizawa M, Mori K, et al.
Cancer Rep (Hoboken)
. 2023 Oct;
:e1926.
PMID: 37903603
Background: A methodology to assess the immune microenvironment (IME) of non-small cell lung cancer (NSCLC) has not been established, and the prognostic impact of IME factors is not yet clear....
7.
Omori S, Muramatsu K, Kawata T, Miyawaki E, Miyawaki T, Mamesaya N, et al.
Invest New Drugs
. 2023 Apr;
41(2):356-364.
PMID: 37036580
B7 homolog 3 protein (B7-H3), an immune checkpoint molecule belonging to the B7 family, has been studied as a target for the development of anti-cancer treatment; however, changes in B7-H3...
8.
Terada Y, Isaka M, Kawata T, Mizuno K, Muramatsu K, Katsumata S, et al.
Jpn J Clin Oncol
. 2022 Dec;
53(2):161-167.
PMID: 36461783
Background: The importance of the stromal components in tumour progression has been discussed widely, but their prognostic role in small size tumours with lepidic components is not fully understood. Applying...
9.
Terada Y, Takahashi T, Hayakawa T, Ono A, Kawata T, Isaka M, et al.
JCO Clin Cancer Inform
. 2022 Sep;
6:e2200070.
PMID: 36162012
Purpose: Several studies reported the possibility of predicting genetic abnormalities in non-small-cell lung cancer by deep learning (DL). However, there are no data of predicting gene rearrangement () using DL....
10.
Yasui K, Kondou R, Miyata H, Iizuka A, Ashizawa T, Nagashima T, et al.
Anticancer Res
. 2022 Aug;
42(9):4417-4428.
PMID: 36039416
Background/aim: The recurrence rate of head and neck squamous cell carcinoma (HNSCC) remains high; thus the control of recurrence is a clinical problem to be challenged. To clarify the precise...